Michael Heffernan
Founder and Chairman
Michael Heffernan is the Founder and Chairman of the Board of Collegium Pharmaceutical. Mike served as President and Chief Executive Officer (CEO) of Collegium Pharmaceutical until June 2018. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. Read more
Garen Bohlin
Garen Bohlin held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Mr. Bohlin was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline). Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals (acquired by Biogen). Read more
Joseph Ciaffoni
President and CEO
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Mr. Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Read more
John A. Fallon, M.D.
Dr. John Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts (BCBS) from 2004 through 2015. Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer (CEO) for clinical affairs at the State University of New York Downstate Medical Center. His professional experience includes the Partners Healthcare System, where he was Chairman of the physician network. Read more
John G. Freund, M.D.
Dr. John G. Freund co-founded Skyline Ventures in 1997 and has served as a Partner at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. Previously, he co-founded Intuitive Surgical, a medical device company, and served on its Board of Directors. Read more
David Hirsch, Ph.D., M.D.
David Hirsch is a founder and Managing Director of Longitude Capital where he focuses on investments in biotechnology. Previously, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. Read more
Gwen A. Melincoff
Gwen Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently Managing Director at Gemini Advisors LLC and an advisor to Phase 1 Ventures and Verge Genomics. Previously, she served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company. Read more
Gino Santini
Gino Santini is a senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotech companies. He currently serves on the Boards of Directors of AMAG Pharmaceuticals, Horizon Pharma and Allena Pharmaceuticals. He retired as Senior Vice President of Corporate Strategy and Business Development of Eli Lilly after a career with the company of over 27 years. Read more
Theodore Schroeder
Theodore Schroeder is the President, CEO, Director and co-founder of Zavante Therapeutics, Inc. Previously, Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt) and served as its President and Chief Executive Officer, and as a member of the Board of Directors. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals, including Senior Vice President of North America Sales and Marketing and Vice President and General Manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals (acquired by Elan). Read more